WO2011093647A3 - Genes implicated in osteoarthritis and use thereof - Google Patents

Genes implicated in osteoarthritis and use thereof Download PDF

Info

Publication number
WO2011093647A3
WO2011093647A3 PCT/KR2011/000554 KR2011000554W WO2011093647A3 WO 2011093647 A3 WO2011093647 A3 WO 2011093647A3 KR 2011000554 W KR2011000554 W KR 2011000554W WO 2011093647 A3 WO2011093647 A3 WO 2011093647A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
osteoarthritis
treating arthritis
genes implicated
arthritis
Prior art date
Application number
PCT/KR2011/000554
Other languages
French (fr)
Other versions
WO2011093647A2 (en
Inventor
Dae-Won Kim
Original Assignee
Industry-Academic Cooperation Foundation, Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100006890A external-priority patent/KR101150900B1/en
Priority claimed from KR1020100006898A external-priority patent/KR101145348B1/en
Application filed by Industry-Academic Cooperation Foundation, Yonsei University filed Critical Industry-Academic Cooperation Foundation, Yonsei University
Publication of WO2011093647A2 publication Critical patent/WO2011093647A2/en
Publication of WO2011093647A3 publication Critical patent/WO2011093647A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a composition for preventing or treating arthritis, a diagnosis kit for arthritis, a method for screening a composition for treating arthritis and a method for preventing or treating arthritis. The present invention ensures the maintenance and survival of chondrocytes essential for physiological functions of connective tissue, such that it is promising for preventing or treating arthritis fundamentally.
PCT/KR2011/000554 2010-01-26 2011-01-26 Genes implicated in osteoarthritis and use thereof WO2011093647A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0006898 2010-01-26
KR10-2010-0006890 2010-01-26
KR1020100006890A KR101150900B1 (en) 2010-01-26 2010-01-26 Compositions for Treating Osteoarthritis
KR1020100006898A KR101145348B1 (en) 2010-01-26 2010-01-26 Gene Implicated in Osteoarthritis and Use Thereof

Publications (2)

Publication Number Publication Date
WO2011093647A2 WO2011093647A2 (en) 2011-08-04
WO2011093647A3 true WO2011093647A3 (en) 2012-01-05

Family

ID=44319985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000554 WO2011093647A2 (en) 2010-01-26 2011-01-26 Genes implicated in osteoarthritis and use thereof

Country Status (1)

Country Link
WO (1) WO2011093647A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016095934A2 (en) * 2014-12-14 2016-06-23 El Abd Hisham Mohamed Magdy A novel genetic device to engineer cell behavior
WO2018088813A2 (en) 2016-11-09 2018-05-17 아이씨엠 주식회사 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
US11628203B2 (en) 2018-10-19 2023-04-18 Icm Co., Ltd. Pharmaceutical composition for treating retinal dystrophies, comprising Nkx3.2 and fragment thereof as active ingredients

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHURCH, V. ET AL.: "Expression and function of Bapxl during chick limb development", ANAT EMBRYOL., vol. 209, 2005, pages 461 - 469 *
DATABASE GENBANK 17 October 2000 (2000-10-17), accession no. NCBI Database accession no. AF213356 *
DATABASE PROTEIN 13 January 2008 (2008-01-13), accession no. NCBI Database accession no. NP_001180 *
PARK, M. ET AL.: "Constitutive RelA activation mediated by Nkx3.2 controls chondrocyte viability", NAT CELL BIOL., vol. 9, no. 3, 18 February 2007 (2007-02-18), pages 287 - 298 *

Also Published As

Publication number Publication date
WO2011093647A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
MX343135B (en) Fumagillol type compounds and methods of making and using same.
IN2012DN02737A (en)
MX344238B (en) Tetrazole compounds and methods of making and using same.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX338535B (en) Ibat inhibitors for the treatment of liver diseases.
WO2012062925A3 (en) Compounds and methods for treating pain
UA108198C2 (en) Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
WO2012154679A8 (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same
EA201000559A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF ANTIBODIES TO SKLEROSTIN
EP2563406A4 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
WO2009155513A3 (en) Immunoglobulins with reduced aggregation
WO2011088123A3 (en) Wnt antagonists and methods of treatment and screening
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MX2018009553A (en) Screening methods.
TN2011000482A1 (en) Organic compounds and their uses
MX356755B (en) Fumigillol type compounds and methods of making and using same.
PL2408718T3 (en) Composition based on calcium hydroxide, method for the production thereof and use of same for treating water and mud
WO2012044997A3 (en) Kits, components and methods for tissue reconstruction
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
PL2384339T3 (en) Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1)
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MY155330A (en) Methods for salt production
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
MX357166B (en) Antibodies to notum pectinacetylesterase.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11737286

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11737286

Country of ref document: EP

Kind code of ref document: A2